Breast CancerBREVIANCT07492043
Breast Tumour Size Measurement by Field Cycling Imaging
An observational study of Breast Cancer and Ductal Carcinoma In Situ, run by University of Aberdeen at 1 site in United Kingdom.
Trial summary
The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately estimate tumour size in patients with a type of breast cancer called ductal carcinoma in situ (DCIS). Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer, Ductal Carcinoma In Situ
- What is being tested?
- Field-Cycling Imaging research scan and 3T MRI research scan
- How many people
- 12 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Apr 2026to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Female patients from the Breast Unit of Aberdeen Royal Infirmary diagnosed with DCIS on clinical imaging with a breast tumour of at least 1 cm on imaging undergoing surgery.
Who may be able to join
- Females ≥ 18 years old.
- Subjects diagnosed with DCIS on initial biopsy.
- Lesion size >1 cm on imaging.
- Subjects undergoing surgery as part of their treatment.
- Able to fit comfortably in the scanners.
- Able to understand written and spoken English.
Who cannot join
- Subjects undergoing chemotherapy or hormonal therapy.
- Individuals unable to give informed consent.
- Contra-indications to MRI scanning such as implantable cardiac devices.
- Known allergy to contrast agent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site
University of Aberdeen
Aberdeen
Vasiliki Mallikourti, PhD, +44 1224 437831, vasiliki.mallikourti@abdn.ac.uk
Gerald Lip, Dr, gerald.lip@nhs.scot
About this study
The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately estimate tumour size in patients with a type of breast cancer called ductal carcinoma in situ (DCIS). The main question it aims to answer is:
Can FCI accurately estimate DCIS lesion size compared with histology results?
Participants will have a standard MRI scan and an FCI scan before undergoing surgery to remove the tumour.
- Conditions
- Breast Cancer, Ductal Carcinoma In Situ
- Being tested
- Field-Cycling Imaging research scan, 3T MRI research scan
- Keywords
- Field-Cycling Imaging, FCI, DCIS, Breast Cancer
- Medical subject headings
- Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Field-Cycling Imaging research scanOther
Baseline FCI scan
3T MRI research scanOther
Baseline MRI scan
| Study group | Role | What they receive |
|---|---|---|
| Breast Cancer | Participants with breast cancer of ductal carcinoma in-situ (DCIS) who are due to undergo surgical treatment. Receives: Other: Field-Cycling Imaging research scan; Other: 3T MRI research scan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Accuracy of DCIS lesion size estimation using FCI, validated against histopathological measurements (gold standard).
Extent of agreement between lesion size estimation by FCI and actual lesion size according to NHS histopathology results.
Measured: Baseline
Secondary outcomes (1)
Comparison of DCIS lesion measurements using FCI and 3T MRI.
Extent of agreement in lesion size measurements between FCI and conventional 3T MRI.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Mar 2026
- Study startApr 2026 (estimated)
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Aberdeen
- Sponsor type
- University, hospital or other
- Collaborators
- NHS Grampian
- Responsible party
- Sponsor
- Investigators
- Vasiliki Mallikourti, PhD, Study chair, University of Aberdeen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07492043
- Sponsor's protocol ID
- 2-082-25
- Other IDs
- 25/NW/0355
- Acronym
- BREVIA
- Status last verified
- Mar 2026
- First submitted
- 19 Mar 2026
- Last updated
- 25 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Mallikourti V, Ross PJ, Maier O, Hanna K, Husain E, Davies GR, Lurie DJ, Lip G, Lahrech H, Masannat Y, Broche LM. Field cycling imaging to characterise breast cancer at low and ultra-low magnetic fields below 0.2 T. Commun Med (Lond). 2024 Oct 30;4(1):221. doi: 10.1038/s43856-024-00644-2.
PubMed 39478081
Study at a glance
From the registry record, last updated by the sponsor on 25 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Breast Tumour Size Measurement by Field Cycling Imaging
- ClinicalTrials.gov ID
- NCT07492043
- Acronym / sponsor ID
- BREVIA / 2-082-25
- Conditions
- Breast Cancer, Ductal Carcinoma In Situ
- Keywords
- Field-Cycling Imaging, FCI, DCIS, Breast Cancer
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- University of AberdeenUniversity, hospital or other
- Collaborators
- NHS Grampian
- Study start
- Apr 2026 (estimated)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 25 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately estimate tumour size in patients with a type of breast cancer called ductal carcinoma in situ (DCIS). The main question it aims to answer is:
Can FCI accurately estimate DCIS lesion size compared with histology results?
Participants will have a standard MRI scan and an FCI scan before undergoing surgery to remove the tumour.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Breast Cancer | – | Other: Field-Cycling Imaging research scan, Other: 3T MRI research scanParticipants with breast cancer of ductal carcinoma in-situ (DCIS) who are due to undergo surgical treatment. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Female patients from the Breast Unit of Aberdeen Royal Infirmary diagnosed with DCIS on clinical imaging with a breast tumour of at least 1 cm on imaging undergoing surgery.
Key inclusion criteria (6 listed)
- Females ≥ 18 years old.
- Subjects diagnosed with DCIS on initial biopsy.
- Lesion size >1 cm on imaging.
- Subjects undergoing surgery as part of their treatment.
- Able to fit comfortably in the scanners.
Key exclusion criteria (4 listed)
- Subjects undergoing chemotherapy or hormonal therapy.
- Individuals unable to give informed consent.
- Contra-indications to MRI scanning such as implantable cardiac devices.
- Known allergy to contrast agent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Field-Cycling Imaging research scanBaseline FCI scan | Other | Breast Cancer |
| 3T MRI research scanBaseline MRI scan | Other | Breast Cancer |
Primary outcome
Accuracy of DCIS lesion size estimation using FCI, validated against histopathological measurements (gold standard).
Time frame: Baseline
Extent of agreement between lesion size estimation by FCI and actual lesion size according to NHS histopathology results.
1 secondary outcome
Comparison of DCIS lesion measurements using FCI and 3T MRI.
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Mar 2026.
- Background: PubMed 39478081Mallikourti V, Ross PJ, Maier O, Hanna K, Husain E, Davies GR, Lurie DJ, Lip G, Lahrech H, Masannat Y, Broche LM. Field cycling imaging to characterise breast cancer at low and ultra-low magnetic fields below 0.2 T. Commun Med (Lond). 2024 Oct 30;4(1):221. doi: 10.1038/s43856-024-00644-2.
- Individual participant dataSharing planned: Undecided
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Vasiliki Mallikourti, PhD study chair
University of Aberdeen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer and Ductal Carcinoma In Situ, run by University of Aberdeen at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 25 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Vasiliki Mallikourti, PhD (+44 1224 437831, vasiliki.mallikourti@abdn.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Accuracy of DCIS lesion size estimation using FCI, validated against histopathological measurements (gold standard). (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07492043, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Mar 2026.